Thymic Peptides & Immunomodulation: A Research Literature Overview

NOVA Q Research · Research Library

Thymic Peptides & Immunomodulation: A Research Literature Overview

What the published research examines across Thymosin Alpha-1 (thymalfasin) and Thymalin — a chemically defined synthetic peptide with a large international literature, and a tissue-derived preparation studied mainly by Russian groups.

Neutral literature aggregation · Compiled by NOVA Q Research · Updated 2026-07-24 · 8 cited sources
In brief
  • Thymosin Alpha-1 (thymalfasin, Zadaxin) is registered as a pharmaceutical in a number of countries but is investigational and not FDA-approved in the US.
  • Its clinical literature spans chronic hepatitis, sepsis, viral respiratory infection, and vaccine response — with mixed results (the large phase-3 TESTS sepsis trial did not show a significant mortality difference).
  • Thymalin is a tissue-derived preparation with a smaller literature concentrated in Russian groups and limited independent replication.

Thymic peptides are naturally occurring and synthetically reproduced polypeptides originally isolated from thymus tissue, studied for effects on T-lymphocyte differentiation and broader immune signaling. The two compounds here differ substantially in the volume, geography, and methodological character of their evidence: Thymosin Alpha-1 is a chemically defined synthetic peptide with an extensive international clinical literature and pharmaceutical registration in several countries; Thymalin is a tissue-derived polypeptide fraction whose published base is concentrated in Russian and post-Soviet research.

Thymosin Alpha-1 (thymalfasin, Zadaxin)

Class / mechanism. A synthetic 28-amino-acid acetylated peptide corresponding to a fragment of prothymosin alpha, described as an immunomodulator; proposed mechanisms include Toll-like-receptor signaling and effects on T-cell maturation and cytokine profiles.

Thymosin Alpha-1 has one of the larger clinical literatures in this category, spanning randomized controlled trials, cohorts, and systematic reviews across chronic viral hepatitis, sepsis, viral respiratory infection (including COVID-19), and vaccine response in older adults. Its regulatory status is heterogeneous — registered in various countries while investigational in others (including the US) — and much of the trial work was conducted in China and Italy.

Selected literature

  1. Chien RN, et al. 1998. “Efficacy of thymosin alpha-1 in chronic hepatitis B: a randomized controlled trial.” Hepatology 27(5):1383–1387. PMID 9581695. https://pubmed.ncbi.nlm.nih.gov/9581695/RCT of thymosin alpha-1 versus control in chronic hepatitis B.
  2. Wu J, et al. 2013. “The efficacy of thymosin alpha-1 for severe sepsis (ETASS): a multicenter randomized controlled trial.” Crit Care 17(1):R8. PMID 23327199. https://pubmed.ncbi.nlm.nih.gov/23327199/Multicenter RCT of 28-day mortality and immune markers in severe sepsis.
  3. Wu J, et al. 2025. “Thymosin α1 for sepsis (TESTS): a phase 3 randomized placebo-controlled trial.” BMJ. PMID 39814420. https://pubmed.ncbi.nlm.nih.gov/39814420/Large phase-3 trial of 28-day all-cause mortality in sepsis.
  4. Gravenstein S, et al. 1989. “Augmentation of influenza antibody response in elderly men by thymosin alpha one.” J Am Geriatr Soc 37(1):1–8. PMID 2642497. https://pubmed.ncbi.nlm.nih.gov/2642497/Double-blind placebo-controlled study of influenza-vaccine antibody response.
  5. Sun Q, et al. 2021. “The effect of thymosin α1 on mortality of critical COVID-19 patients: a multicenter retrospective study.” Int Immunopharmacol 90:107143. PMID 33208294. https://pubmed.ncbi.nlm.nih.gov/33208294/Multicenter retrospective study of associations with mortality in critical COVID-19.
Where the evidence is limited. Results across indications are mixed and methodologically heterogeneous — the large phase-3 TESTS sepsis trial did not show a significant mortality difference versus placebo, and much COVID-19 evidence is retrospective. Geographic concentration of trials, varied dosing and endpoints, and US non-approval limit generalizability.

Thymalin

Class / mechanism. A polypeptide complex extracted from bovine (calf) thymus tissue, described as a “peptide bioregulator” rather than a single defined molecule; reported to modulate T-lymphocyte populations. As a tissue-derived fraction, its composition and standardization differ fundamentally from the defined Thymosin Alpha-1.

Thymalin’s published literature is substantially smaller than Thymosin Alpha-1’s and is heavily concentrated in Russian and post-Soviet research groups (Khavinson, Morozov, and collaborators), appearing largely in gerontology and immunology journals. It has historical use as a registered immunomodulatory preparation in Russia, with research emphasizing immune-status regulation, aging themes, and — more recently — exploratory use in severe respiratory infection.

Selected literature

  1. Morozov VG, Khavinson VKh. 1997. “Natural and synthetic thymic peptides as therapeutics for immune dysfunction.” Int J Immunopharmacol 19(9–10):501–505. PMID 9637345. https://pubmed.ncbi.nlm.nih.gov/9637345/Review by the originating group of thymus-derived and synthetic thymic peptides.
  2. Khavinson VKh, Morozov VG. 2003. “Peptides of pineal gland and thymus prolong human life.” Neuro Endocrinol Lett 24(3–4):233–240. PMID 14523363. https://pubmed.ncbi.nlm.nih.gov/14523363/Report summarizing long-term follow-up the authors associate with thymic/pineal peptides.
  3. Kuznik B, et al. 2021. “Peptide drug thymalin regulates immune status in severe COVID-19 older patients.” Adv Gerontol 11(4). https://doi.org/10.1134/S2079057021040068Comparative clinical study of immune markers and course when thymalin was added to standard care.
Where the evidence is limited. The base is limited by geographic and group concentration, older publication dates, small sample sizes, and few large independent placebo-controlled RCTs outside the originating networks; several key reports are reviews rather than primary trials. As a tissue-derived preparation, composition standardization further constrains interpretation.

How to read this report

This report aggregates published scientific literature for the compounds NOVA Q Research supplies in the Immune category. It describes what studies investigated, the models used, and the maturity of the evidence. It does not evaluate, recommend, or imply any use in humans or animals, and it is not medical, veterinary, or research-protocol advice. Where the record is preclinical or geographically concentrated, we say so. Every source is cited so it can be checked independently.

Browse the Immune catalog →
For research use only. Not for human or veterinary use. NOVA Q Research supplies research-grade materials for laboratory research use only. Nothing in this document is intended to diagnose, treat, cure, or prevent any disease, or to guide human or veterinary use. Statements have not been evaluated by the FDA. Citations are provided for reference and do not imply endorsement.